Cell Therapy

Can Gene Editing Cure Chronic Hepatitis B?
Research & Development Can Gene Editing Cure Chronic Hepatitis B?

With over 300 million people globally suffering from chronic hepatitis B, the disease presents a monumental challenge in the realm of public health. Traditional treatments have mainly focused on suppressing the virus rather than providing a cure, demanding lifelong therapy for many patients.

How Are Innovations in Medicine and Nanotech Changing Lives?
Tech & Innovation How Are Innovations in Medicine and Nanotech Changing Lives?

Ivan Kairatov is a distinguished figure in the biopharma industry, renowned for his expertise in tech and innovation within the field. With a robust background in research and development, Ivan has substantially influenced advancements in cellular therapies and drug development. Today, we delve

ASU Study Uncovers Surprising Healing Mechanism in Necrotic Cells
Biotech & Bioprocessing ASU Study Uncovers Surprising Healing Mechanism in Necrotic Cells

A groundbreaking study from Arizona State University (ASU) has discovered remarkable insights about a potentially new healing process prompted by necrosis, the premature death of cells. This unexpected phenomenon, observed in fruit flies known for their regenerative capabilities, may have profound

How Will Landmark Bio Shape Artis Biosolutions' Future?
Biotech & Bioprocessing How Will Landmark Bio Shape Artis Biosolutions' Future?

Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key player

Can CAR T-Cell Therapy Transform Treatment for Systemic Sclerosis?
Research & Development Can CAR T-Cell Therapy Transform Treatment for Systemic Sclerosis?

The medical landscape has been witnessing a groundbreaking shift with the advent of novel therapies aimed at tackling some of the most challenging conditions. One such development is the Phase 1/2 clinical trial of Cabaletta Bio's CAR T-cell therapy, rese-cel (resecabtagene autoleucel), targeting

Impact of Peter Marks' Departure on Cell and Gene Therapy at FDA
Research & Development Impact of Peter Marks' Departure on Cell and Gene Therapy at FDA

The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later